Literature DB >> 7810992

Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

M R Hammerschlag1.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7810992      PMCID： PMC284655          DOI： 10.1128/AAC.38.9.1873

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  36 in total

1.  Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics.

Authors:  R B Jones; B Van der Pol; D H Martin; M K Shepard
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

Authors:  K Chirgwin; P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

3.  Use of HL cells for improved isolation and passage of Chlamydia pneumoniae.

Authors:  L D Cles; W E Stamm
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

Review 4.  Susceptibility testing of Chlamydia trachomatis: from eggs to monoclonal antibodies.

Authors:  J M Ehret; F N Judson
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

5.  Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.

Authors:  B A Lipsky; K J Tack; C C Kuo; S P Wang; J T Grayston
Journal:  Am J Med       Date:  1990-12       Impact factor: 4.965

Review 6.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

7.  In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  A Agacfidan; J Moncada; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis.

Authors:  J T Grayston; M B Aldous; A Easton; S P Wang; C C Kuo; L A Campbell; J Altman
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

9.  Chlamydia pneumoniae strain TWAR, Mycoplasma pneumoniae, and viral infections in acute respiratory disease in a university student health clinic population.

Authors:  D H Thom; J T Grayston; S P Wang; C C Kuo; J Altman
Journal:  Am J Epidemiol       Date:  1990-08       Impact factor: 4.897

10.  Factors affecting viability and growth in HeLa 229 cells of Chlamydia sp. strain TWAR.

Authors:  C C Kuo; J T Grayston
Journal:  J Clin Microbiol       Date:  1988-05       Impact factor: 5.948
View more
  24 in total

1.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  The Role of Chlamydia in Upper Respiratory Tract Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-04       Impact factor: 3.725

Review 3.  Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember?

Authors:  Kensuke Shima; Gregor Kuhlenbäumer; Jan Rupp
Journal:  Med Microbiol Immunol       Date:  2010-05-06       Impact factor: 3.402

4.  Current knowledge of Chlamydia pneumoniae and atherosclerosis.

Authors:  M R Hammerschlag
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-05       Impact factor: 3.267

5.  In vitro activities of doxycycline and enrofloxacin against European Chlamydia psittaci strains from turkeys.

Authors:  P Butaye; R Ducatelle; P De Backer; H Vermeersch; J P Remon; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Prospective study of epidemiology and prognostic factors in community-acquired pneumonia.

Authors:  J Gómez; V Baños; J Ruiz Gómez; M C Soto; L Muñoz; M L Nuñez; M Canteras; M Valdés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-07       Impact factor: 3.267

7.  N-acylated derivatives of sulfamethoxazole and sulfafurazole inhibit intracellular growth of Chlamydia trachomatis.

Authors:  Sania Marwaha; Hanna Uvell; Olli Salin; Anders E G Lindgren; Jim Silver; Mikael Elofsson; Asa Gylfe
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

8.  In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

Authors:  H M Freidank; P Losch; H Vögele; M Wiedmann-Al-Ahmad
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

9.  In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae.

Authors:  J Gnarpe; K Eriksson; H Gnarpe
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.